Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00648830 | Comparative Bioavailability Study of Clarithromycin 250 mg Tablets | PHASE1 | COMPLETED | 32 | — | — | May 1, 2004 | Jun 1, 2004 | Apr 24, 2024 | 1 | Canada |
| NCT00648960 | Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fasting State | PHASE1 | COMPLETED | 64 | — | — | Jul 1, 2003 | Jul 1, 2003 | Apr 1, 2008 | 1 | Canada |
| NCT00648128 | Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fed State | PHASE1 | COMPLETED | 44 | — | — | Mar 1, 2003 | Mar 1, 2003 | Apr 1, 2008 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Clarithromycin 250 mg immediate-release oral tablet |
| 2 | ACTIVE_COMPARATOR | Biaxin® (Clarithromycin) 250 mg tablet |
| Name | Type | Description |
|---|---|---|
| Clarithromycin | PROCEDURE | Single-dose of Clarithromycin 250 mg oral immediate-release tablets |
Inclusion Criteria: Subjects meeting all of the following criteria may be included in the study: Availability of volunteer for the entire study period and willingness to adhere to protocol requirements as evidenced by the informed consent form (ICF) duly signed by the volunteer Males or females a...